奧洛茲美醫療 HALO 深 滬
等待開盤 05-19 09:30:00 美东时间
67.44
+0.320
+0.48%
華盛通- 最 高69.3199
- 今 開68.03
- 成交量 178.09万股
- 最 低 66.90
- 昨 收 67.12
- 總市值 799.93万
- 52周最高 82.22
- 市盈率 靜 26.37
- 換手率 1501.44%
- 52周最低 51.06
- 委 比 -98.82%
- 總股本 0.00亿
- 歷史最高 82.22
- 量 比 0.61
- 振 幅 3.61%
- 歷史最低 3.86
- 每 手 1
- 風險率 7.08%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
Halozyme Earnings Call Highlights Royalty-Fueled Growth
Halozyme Therapeutics (($HALO)) has held its Q1 earnings call. Read on for the ...
05-13 08:25
电话会总结 ｜ Halozyme(HALO)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Halozyme业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 总营收：3.77亿美元，同比增长42% - 特许权使用费收入：2.41亿美元，同比增长43%，主要由DARZALEX、VYVGART Hytrulo和PHESGO推动 **盈利能力：** - 调整后EBITDA：2.30亿美元，同比增长超过40% - 调整后EBITDA利润率：约61%（2.30亿/3.77亿） - Non-GAAP每股收益：1.60美元，同比增长44%（从1.11美元增至1.60美元） - GAAP每股收益：1.22美元，同比增长
05-12 12:02
Halozyme Therapeutics Affirms FY2026 Adj EPS Guidance of $7.75-$8.25 vs $8.09 Est; Affirms FY2026 Sales Guidance of $1.710B-$1.810B vs $1.760B Est
Halozyme Therapeutics (NASDAQ:HALO) affirms FY2026 Adj EPS guidance from $7.75-$8.25 to $7.75-$8.25 vs $8.09 analyst estimate. Affirms FY2026 sales outlook from $1.710 billion-$1.810 billion to $1.710 billion-$1.810
05-12 04:58
Halozyme Therapeutics Q1 Adj. EPS $1.60 Beats $1.53 Estimate, Sales $376.708M Beat $359.053M Estimate
Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $1.60 per share which beat the analyst consensus estimate of $1.53 by 4.58 percent. This is a 44.14 percent increase over earnings of $1.11 per share
05-12 04:03
Earnings Scheduled For May 11, 2026
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
GSK licenses Halozyme's Enhanze drug delivery technology
Halozyme Therapeutics (HALO) announced on Thursday that GSK (GSK) has reached an agreement to license its Enhanze drug delivery technology to advance subcutaneously delivered cancer drugs. The compani...
05-08 01:01
Halozyme Therapeutics Signs License Agreement With GSK For ENHANZE Drug Delivery Technology To Develop, Commercialize Subcutaneous Administration Of Multiple Oncology Targets
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced the Company entered into a global collaboration and license agreement with GSK. Under the collaboration, GSK has licensed
05-07 21:07
Halozyme Appoints Darren Snellgrove as Chief Financial Officer
SAN DIEGO, April 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of Darren Snellgrove as Chief Financial Off...
04-30 20:00
美股大行评级 | 瑞银：维持Visa"买入"评级！目标价从390美元升至410美元
今日重点评级关注：HC Wainwright & Co.：维持Protara Therapeutics"买入"评级，目标价从23美元升至27美元；BTIG：维持Black Diamond Therapeutic"买入"评级，目标价从10美元升至11美元
04-30 19:24
